Avalo Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.1025
- Today's High:
- $0.1679
- Open Price:
- $0.1396
- 52W Low:
- $1.41
- 52W High:
- $7.4136
- Prev. Close:
- $0.085
- Volume:
- 279173355
Company Statistics
- Market Cap.:
- $38.15 million
- Book Value:
- -0.475
- Revenue TTM:
- $17.35 million
- Operating Margin TTM:
- -146.25%
- Gross Profit TTM:
- $-7939000
- Profit Margin:
- -170.36%
- Return on Assets TTM:
- -32.33%
- Return on Equity TTM:
- -77794.73%
Company Profile
Avalo Therapeutics Inc had its IPO on 2015-11-13 under the ticker symbol AVTX.
The company operates in the Healthcare sector and Biotechnology industry. Avalo Therapeutics Inc has a staff strength of 20 employees.
Stock update
Shares of Avalo Therapeutics Inc opened at $0.14 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.1 - $0.17, and closed at $0.12.
This is a +45.29% increase from the previous day's closing price.
A total volume of 279,173,355 shares were traded at the close of the day’s session.
In the last one week, shares of Avalo Therapeutics Inc have increased by +35.71%.
Avalo Therapeutics Inc's Key Ratios
Avalo Therapeutics Inc has a market cap of $38.15 million, indicating a price to book ratio of 5.8996 and a price to sales ratio of 3.159.
In the last 12-months Avalo Therapeutics Inc’s revenue was $17.35 million with a gross profit of $-7939000 and an EBITDA of $-25247000. The EBITDA ratio measures Avalo Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Avalo Therapeutics Inc’s operating margin was -146.25% while its return on assets stood at -32.33% with a return of equity of -77794.73%.
In Q1, Avalo Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 59.5%.
Avalo Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.95 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Avalo Therapeutics Inc’s profitability.
Avalo Therapeutics Inc stock is trading at a EV to sales ratio of 3.2844 and a EV to EBITDA ratio of -1.1188. Its price to sales ratio in the trailing 12-months stood at 3.159.
Avalo Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $36.24 million
- Total Liabilities
- $23.25 million
- Operating Cash Flow
- $-133000.00
- Capital Expenditure
- $158000
- Dividend Payout Ratio
- 0%
Avalo Therapeutics Inc ended 2024 with $36.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $36.24 million while shareholder equity stood at $-6267000.00.
Avalo Therapeutics Inc ended 2024 with $5.16 million in deferred long-term liabilities, $23.25 million in other current liabilities, 13000.00 in common stock, $-313779000.00 in retained earnings and $14.41 million in goodwill. Its cash balance stood at $16.69 million and cash and short-term investments were $16.69 million. The company’s total short-term debt was $9,296,000 while long-term debt stood at $10.47 million.
Avalo Therapeutics Inc’s total current assets stands at $19.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $857000.00 compared to accounts payable of $5.57 million and inventory worth $19000.00.
In 2024, Avalo Therapeutics Inc's operating cash flow was $-133000.00 while its capital expenditure stood at $158000.
Comparatively, Avalo Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.12
- 52-Week High
- $7.4136
- 52-Week Low
- $1.41
- Analyst Target Price
- $7.33
Avalo Therapeutics Inc stock is currently trading at $0.12 per share. It touched a 52-week high of $7.4136 and a 52-week low of $7.4136. Analysts tracking the stock have a 12-month average target price of $7.33.
Its 50-day moving average was $0.2 and 200-day moving average was $2.63 The short ratio stood at 1.45 indicating a short percent outstanding of 0%.
Around 1162.1% of the company’s stock are held by insiders while 5655.6% are held by institutions.
Frequently Asked Questions About Avalo Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company’s drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn’s disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.